<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787354</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG ST21-05</org_study_id>
    <nct_id>NCT04787354</nct_id>
  </id_info>
  <brief_title>Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)</brief_title>
  <official_title>A Randomized Phase 3 Clinical Trial Investigating Optimal Duration of Oxaliplatin Administration in Postoperative XELOX (Oxaliplatin + Capecitabine) Adjuvant Chemotherapy for the Patients With Stage II/III Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4&#xD;
      cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX&#xD;
      treatment (8 cycles of XELOX).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XELOX (oxaliplatin + capecitabine) combination chemotherapy is considered a standard adjuvant&#xD;
      treatment for curatively resected gastric cancer patients after it proved its effecacy in the&#xD;
      CLASSIC trial. Adjuvant XELOX chemotherapy is a long-term treatment with a total treatment&#xD;
      period of 6 months and it is known that about 33% of patients cannot complete treatment&#xD;
      schedule due to side effects. In particular, peripheral neuropathy, which is caused by the&#xD;
      cumulative administration of oxaliplatin, is a major cause of lowering the patient's quality&#xD;
      of life and treatment compliance, and it is known that the incidence rate increases when&#xD;
      standard XELOX treatment is continued for more than 6 cycles. In colorectal cancer, clinical&#xD;
      studies have been actively conducted to shorten the duration of standard adjuvant&#xD;
      chemotherapy to reduce the peripheral sensory neuropathy caused by oxaliplatin, but there are&#xD;
      no relevant studies in gastric cancer.&#xD;
&#xD;
      This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4&#xD;
      cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX&#xD;
      treatment (8 cycles of XELOX).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>The disease-free survival (DFS) will be measured from the start of study treatment until documented tumor progression (by RECIST) or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5-year</time_frame>
    <description>The overall survival (OS) will be estimated from the start of study treatment until participant's death and measured using the Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profiles</measure>
    <time_frame>3-year</time_frame>
    <description>Adverse events will be graded using the NCI common terminology criteria for adverse events (NCTCAE) v 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1069</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard adjuvant XELOX 8 cycles&#xD;
Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, total 8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant XELOX 4 cycles followed by capecitabine monotherapy 4 cycles&#xD;
Oxaliplatin: 130 mg/m2/day(day 1) Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles&#xD;
followed by&#xD;
Capecitabine: 2,000 mg/m2/day(day 1-14), q 3weeks, 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin: 130 mg/m2/day</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: 2,000 mg/m2/day</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed gastric or gastroesophageal junction&#xD;
             adenocarcinoma patients who underwent curative surgery (D1 beta or D2 resection)&#xD;
&#xD;
          -  Pathologically confirmed stage II, III patients (AJCC 8th edition)&#xD;
&#xD;
          -  Age 19 years and older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2&#xD;
&#xD;
          -  Adequate marrow function (ANC &gt; 1,500/uL, Platelet &gt;100,000/uL, Hb &gt; 8.0 g/dL,&#xD;
             patients with chronic anemia who require intermittent blood transfusions can also&#xD;
             participate in the study)&#xD;
&#xD;
          -  Adequate renal function, with serum creatinine &lt; 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
          -  Adequate hepatic function with serum total bilirubin ≤ 1.5 x ULN, alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN&#xD;
&#xD;
          -  Written, informed consent to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Positive pregnancy test at baseline (postmenopausal women should be amenorrhea for at&#xD;
             least 12 months to be considered non-fertile)&#xD;
&#xD;
          -  Sexually active men and women who are not willing to implement contraception during&#xD;
             study and until 3 months after discontinuation of study drug&#xD;
&#xD;
          -  Evidence of metastasis (including cytologically confirmed malignant ascites)&#xD;
&#xD;
          -  Prior systemic chemotherapy or radiation therapy for stomach cancer&#xD;
&#xD;
          -  Patients who have not recovered from serious complications of gastrectomy&#xD;
&#xD;
          -  History of other malignancies within the last 3 years (excluding adequately treated&#xD;
             basal cell carcinoma of the skin, in situ cancer of the cervix, non-metastatic thyroid&#xD;
             cancer)&#xD;
&#xD;
          -  A history of clinically significant uncontrolled seizures, central nervous system&#xD;
             disorders, or mental disorders, which make it impossible to understand the informed&#xD;
             consent or interfere with compliance with oral drug intake&#xD;
&#xD;
          -  Clinically significant (i.e., active) heart disease: e.g. unstable angina requiring&#xD;
             medication, symptomatic coronary artery disease, congestive heart failure with NYHA&#xD;
             grade II or higher, severe cardiac arrhythmias or acute coronary syndrome in the past&#xD;
             6 months (including myocardial infarction)&#xD;
&#xD;
          -  Lack of integrity or malabsorption syndrome in the upper gastrointestinal tract, which&#xD;
             is likely to affect the absorption of study drug&#xD;
&#xD;
          -  Serious uncontrolled infection or other serious uncontrolled disease&#xD;
&#xD;
          -  History of allograft requiring immunosuppression therapy&#xD;
&#xD;
          -  Received any investigational drug or procedure within 4 weeks prior to randomization&#xD;
&#xD;
          -  Active viral infection (for hepatitis B carrier, patients can be registered if HBV-DNA&#xD;
             titer is less than 20,000 IU/mL, and are allowed to use prophylactic antiviral agents&#xD;
             by investigator's choice)&#xD;
&#xD;
          -  Active HIV infection&#xD;
&#xD;
          -  Patients with peripheral sensory neuropathy with functional impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hallym University Medical Center</investigator_affiliation>
    <investigator_full_name>Zang, Dae Young</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Chemotherapy, Adjuvant</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

